The metiluracil formula development and availability research of the active principles

Abstract

Introduction: It was statistically proved that each fifth patient who consults a doctor in the Central Europe suffers from a skin disease. The causes of the continual growth of the number of people who suffer of skin diseases are unknown, but it is sure, however, that they are generally due to different types of environmental influences. At the moment, the forms for topical use constitute 4-6% of all the medical forms used in medicine. Among them, 80% are ointments. In this context, it is up-to-date to develop a new pharmaceutical form for external use- an ointment with metiluracil, which shows regenerating and anti-inflammatory properties. Methods: During the research were used some active substances like: metilurcail, excipients and auxiliary materials like: Polyethylene, Vaseline, Lanolin. Solvents: purified water. Special devices for determination and measurements: UV-VIS spectrophotometer Agilent - 8453, the device for determining the dissolution rate, officialized by the Romanian Pharmacopoeia X, commercialized by Erweka Company. Taking into consideration the above, our aim was to develop a soft medical form with metiluracil with different excipients and to study the pharmaceutical availability of these forms. Results: We developed the composition for five soft pharmaceutical forms with metiluracil using different hydrosoluble and liposoluble excipients. The ointments homogeneity was determined according to the Romanian Pharmacopoeia X standards. For each group of ointments was performed the determination of the dissolution rate and pharmaceutical availability. Also, it was determined the kinetics of dissolution and drawn up the concentration and time dependence chart. Conclusions: 1. As a result of metiluracil incorporation with excipients of different nature, we developed five compositions, containing different kind of ointment base. 2. We determined the homogeneity of the proposed ointments. 3. We determined the pharmaceutical availability and the constant of dissolutin rate.